Paris, April 25, 2018 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company […]

Advancement of core pipeline assets on track with key development catalysts expected in 2018 First new molecule generated from platON™, […]

Pipeline reinforced through major development milestones on existing assets and new product acquisition Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext […]

Clinical development plan in line with objectives Livatag® on track to deliver its next important milestone with 90% of patients […]

Exceptional performance linked to international licensing agreements BioAlliance Pharma SA (Euronext Paris-BIO), a company dedicated to the supportive care and […]

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the supportive care and treatment of cancer patients, today […]

Sound cash position of €27.7m as at June 30, 2017 and cash runway till Q1 2019 Development of the core […]

 The company posts a profit as a result of an exceptional revenue High potential for further growth Paris, March 3, […]

2015: Successful year of consolidation and major achievements in all lead programs Progression of Phase III trial of Livatag® in […]

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan […]

Paris (France), April 25, 2017 – 5.45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company […]

Finalization of DRIIV-1 Phase 1 study confirming AsiDNA™ activity and safety profile Initiation of DRIIV-1b study of AsiDNA™ with chemotherapy, […]

Successful key milestones reached on all orphan oncology clinical programs First registration of Sitavig granted in European countries Oravig licensing […]

Expected recurrent revenues BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of […]

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the supportive care and treatment of cancer patients, today […]

– Significant revenues – Net profit for the first semester reflecting the contribution of licensing agreements – Strongly reinforced cash […]

Recurring revenue streams reflect the international deployment of Loramyc® BioAlliance Pharma SA (Euronext Paris –BIO), a company dedicated to specialty […]

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to specialty and orphan oncology products, today reported a consolidated […]

• Key achievements in the clinical development of orphan oncology products • Strongly reinforced cash position after successful capital increase […]

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to specialty and orphan oncology products, today reported a consolidated […]

BioAlliance Pharma confirms the dynamics of its core business BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to […]

• A growth strategy focused on orphan oncology products • Promising products in advanced development • Reinforced cash reserves at […]

• Key achievements in the clinical development programs and especially: – Livatag®: Phase III study opened in France in June […]

• Orphan Oncology Products: recruitment of the first patients in Phase III clinical trial with Livatag® in primary liver cancer […]

Grant of the Marketing Authorization for Sitavig® in the US Strong achievements in clinical trials with Livatag® (phase III) and […]

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of Orphan Oncology Products and to […]

2013: Significant progress on key strategic programs • Livatag® phase III (ReLive): European expansion and authorization from the FDA to […]

BioAlliance Pharma SA (Euronext Paris – BIO), Société d’innovation spécialisée dans le développement de médicaments visant des pathologies orphelines en […]

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

Major evolution of the Company, renamed Onxeo, resulting from the merger between BioAlliance Pharma and Topotarget Good progress of the […]

Quarterly Information as of September 30, 2014 – Effective integration of both entities, BioAlliance Pharma and Topotarget, into newly named […]

Successful strategic merger and acquisition of Danish company Topotarget giving birth to Onxeo Products’ major achievements: Beleodaq® approval in the […]

       Significant advancements of company programs                   – Livatag®: Opening of new centres and active recruitment in the ReLive trial […]

Livatag® Phase III trial in HCC: 50% of patients randomized Scientific recognition of Validive® and Beleodaq® preclinical and clinical data […]

Paris (France), Copenhagen (Denmark), November 5, 2015 – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today published an update on major milestones achieved during the third quarter of 2015 as well as its consolidated revenues for the period ending September 30, 2015. Avancée des programmes cliniques et position solide de trésorerie

Paris, (France), Copenhague, (Danemark), le 5 novembre 2015 – Onxeo SA (Euronext Paris, Nasdaq Copenhague – ONXEO), société innovante spécialisée dans le développement de médicaments orphelins en oncologie, annonce aujourd’hui les principales avancées opérationnelles et le chiffre d’affaires consolidé du 3ème trimestre 2015.

– Expansion of orphan oncology pipeline through acquisition of DNA Therapeutics and lead compound AsiDNATM – Important development milestones on existing […]

Reinforcement of Onxeo’s strategic positioning in the development of innovative oncology treatments Acquisition of DNA Therapeutics and the AsiDNATM product, […]

    Revenues up 55% to €1.2 million     Cash position of €21.7 million at March 31, 2017     All strategic […]

Company completes strategic shift to innovative DNA-targeting programs and platON™ chemistry platform of decoy oligonucleotides Development of lead product AsiDNA™ […]

Development of lead product candidate, AsiDNA™, for the treatment of advanced solid tumors, progressing according to plan DRIIV phase I […]

Clinical development of Onxeo’s lead product candidate AsiDNA™ progressing to plan Preliminary safety and activity results of DRIIV-1 study are […]

AsiDNA™ clinical development progressing to plan First safety and activity results of the phase I DRIIV-1 study expected in Q4 […]

Paris (France), December 20, 2018 – 07:00 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a clinical-stage […]

Clinical development of AsiDNA™ continues in phase 1 study DRIIV-1 Activity of AsiDNA™ demonstrated through the marked activation of its […]

Paris (France), April 8, 2019 – 5:45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company […]